Vaxcyte Inc
Ouvert
SecteurSoins de santé
48.76 2.98
Résumé
Variation du prix de l'action
24h
Min
47.08
Max
48.88
Revenu | -74M -321M |
|---|---|
BPA | -2.3 |
Employés | 507 |
EBITDA | -105M -340M |
Recommandations | Achat Fort |
|---|---|
Prévisions sur 12 Mois | +144.42% upside |
Prochains Résultats | 4 août 2026 |
|---|
Capitalisation Boursière | -1.6B 6.8B |
|---|---|
Ouverture précédente | 45.78 |
Clôture précédente | 48.76 |
Sentiment de l'Actualité
By Acuity
40%
60%
110 / 342 Classement par Healthcare
Vaxcyte Inc Graphique
Les performances passées ne sont pas un indicateur fiable des résultats futurs.
À Propos Vaxcyte Inc
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.